keyword
https://read.qxmd.com/read/38687620/frontotemporal-dementia-from-genetics-to-therapeutic-approaches
#1
REVIEW
Francesca R Buccellato, Marianna D'Anca, Gianluca Martino Tartaglia, Massimo Del Fabbro, Daniela Galimberti
INTRODUCTION: Frontotemporal dementia (FTD) includes a group of neurodegenerative diseases characterized clinically by behavioral disturbances and by neurodegeneration of brain anterior temporal and frontal lobes, leading to atrophy. Apart from symptomatic treatments, there is, at present, no disease-modifying cure for FTD. AREAS COVERED: Three main mutations are known as causes of familial FTD, and large consortia have studied carriers of mutations, also in preclinical Phases...
April 30, 2024: Expert Opinion on Investigational Drugs
https://read.qxmd.com/read/38687432/management-of-heart-failure-in-a-resource-limited-setting-expert-opinion-from-india
#2
REVIEW
Peeyush Jain, Santanu Guha, Soumitra Kumar, J P S Sawhney, Kamal Sharma, K P Sureshkumar, Ashwani Mehta, Rajnish Dhediya, Kumar Gaurav, Rajan Mittal, Bhavesh Kotak
Heart failure poses a global health challenge affecting millions of individuals, and access to guideline-directed medical therapy is often limited. This limitation is frequently attributed to factors such as drug availability, slow adoption, clinical inertia, and delayed diagnosis. Despite international recommendations promoting the use of guideline-directed medical therapy for heart failure management, personalized approaches are essential in settings with resource constraints. In India, crucial treatments like angiotensin II receptor blocker neprilysin inhibitors and sodium-glucose co-transporter 2 inhibitors are not fully utilized despite their established safety and efficacy...
April 30, 2024: Cardiology and Therapy
https://read.qxmd.com/read/38686870/comparison-of-safety-of-acetaminophen-and-ibuprofen-in-minors-based-on-the-faers-database
#3
JOURNAL ARTICLE
Jing Wang, Guowen Feng, Dan Li, Xiaodan Zhou, Jia Chen, Fengdie Wang, Li Chen
OBJECTIVE: To investigate adverse events(ADEs) associated with the use of paracetamol and ibuprofen in people under 18 years of age. BACKGROUND: The use of NSAIDs reached a peak as a result of the spread of COVID-19 in previous years. Minors, as a special population, need to pay more attention to the use of corresponding drugs and the occurrence of adverse events (ADEs). METHODS: The population was divided into four age groups: infant group, preschool group, children group, and adolescent group...
April 30, 2024: Expert Opinion on Drug Safety
https://read.qxmd.com/read/38686865/the-role-of-collagen-triple-helix-repeat-containing-1-cthrc1-in-cancer-development-and-progression
#4
REVIEW
Chandra K Singh, Sofia Fernandez, Gagan Chhabra, Gabriella R Zaemisch, Ayaan Nihal, Jenna Swanlund, Naveed Ansari, Zan Said, Hao Chang, Nihal Ahmad
INTRODUCTION: Collagen triple helix repeat containing 1 (CTHRC1) is a protein that has been implicated in pro-migratory pathways, arterial tissue-repair processes, and inhibition of collagen deposition via the regulation of multiple signaling cascades. Studies have also demonstrated an upregulation of CTHRC1 in multiple cancers where it has been linked to enhanced proliferation, invasion, and metastasis. However, the understanding of the exact role and mechanisms of CTHRC1 in cancer is far from complete...
April 30, 2024: Expert Opinion on Therapeutic Targets
https://read.qxmd.com/read/38686546/drugs-in-preclinical-and-early-clinical-development-for-the-treatment-of-chagas-disease-the-current-status
#5
REVIEW
Fernanda Karoline Vieira da Silva Torchelsen, Ana Lia Mazzeti, Vanessa Carla Furtado Mosqueira
INTRODUCTION: Chagas disease is spreading faster than expected in different countries and little progress has been reported in the discovery of new drugs to combat Trypanosoma cruzi infection in humans. Recent clinical trials have ended with small hope. The pathophysiology of this neglected disease and the genetic diversity of parasites are exceptionally complex. The only two drugs available to treat patients are far from being safe, and their efficacy in the chronic phase is still unsatisfactory...
April 30, 2024: Expert Opinion on Investigational Drugs
https://read.qxmd.com/read/38686498/a-real-world-disproportionality-analysis-of-fda-adverse-event-reporting-system-events-for-ibuprofen
#6
JOURNAL ARTICLE
Yikuan Du, Zhuoming Guo, Bijun Xu, Yujia Yang, Mianda Hu, Yanghui Hu, Yurong Yang, Mengting Zhang, Zhenjie Wang, Xiaochun Guo, Yixing Huang, Jinfeng Zhu, Weichui Zhang, Chun Yang
INTRODUCTION: Ibuprofen is commonly used as an over-the-counter (OTC) antipyretic and analgesic. As the frequency of its use increases, there has been a corresponding increase in reports of associated adverse events (AEs). However, these events have not been systematically reported in the literature. Meanwhile, the importance of effective pharmacovigilance in evaluating the benefits and risks of drugs is being recognized. METHODS: Data were obtained indirectly from FAERS using the OpenVigil 2 database, lexically mapped using software such as MySQL, Microsoft Excel, and the R language, and then subjected to four more rigorous algorithms to detect risk signals associated with ibuprofen AEs...
April 30, 2024: Expert Opinion on Drug Safety
https://read.qxmd.com/read/38685693/advancements-in-the-management-of-obesity-a-review-of-current-evidence-and-emerging-therapies
#7
REVIEW
Mohammed Altigani Abdalla Ahmed, Emmanuel Ssemmondo, Charlotte Mark-Wagstaff, Thozhukat Sathyapalan
INTRODUCTION: Obesity is the modern world's current epidemic, with substantial health and economic impact. This study aimed to provide a narrative overview of the past, currently available, and future treatment options that offer therapeutic and preventive advantages for obesity management. AREAS COVERED: Historically, rimonabant, and lorcaserin, were approved and used for managing non-syndromic obesity. Currently, orlistat, naltrexone/bupropion, glucagon-like peptide-1 receptor agonist (GLP-1 RA), and a few promising therapeutic agents are under investigation, including retatrutide, cagrilintide and orforglipron, which show promising weight reduction effects...
April 29, 2024: Expert Review of Endocrinology & Metabolism
https://read.qxmd.com/read/38685682/lessons-learned-from-the-failure-of-solanezumab-as-a-prospective-treatment-strategy-for-alzheimer-s-disease
#8
JOURNAL ARTICLE
Madia Lozupone, Vittorio Dibello, Rodolfo Sardone, Fabio Castellana, Roberta Zupo, Luisa Lampignano, Ilaria Bortone, Roberta Stallone, Mario Altamura, Antonello Bellomo, Antonio Daniele, Vincenzo Solfrizzi, Francesco Panza
INTRODUCTION: In the last decade, the efforts conducted for discovering Alzheimer's Disease (AD) treatments targeting the best-known pathogenic factors [amyloid-β (Aβ), tau protein, and neuroinflammation] were mostly unsuccessful. Given that a systemic failure of Aβ clearance was supposed to primarily contribute to AD development and progression, disease-modifying therapies with anti-Aβ monoclonal antibodies (e.g. solanezumab, bapineuzumab, gantenerumab, aducanumab, lecanemab and donanemab) are ongoing in randomized clinical trials (RCTs) with contrasting results...
April 29, 2024: Expert Opinion on Drug Discovery
https://read.qxmd.com/read/38685429/enhancing-vulnerability-assessment-through-spatially-explicit-modeling-of-mountain-social-ecological-systems-exposed-to-multiple-environmental-hazards
#9
JOURNAL ARTICLE
Saied Pirasteh, Yiming Fang, Davood Mafi-Gholami, Ammar Abulibdeh, Akram Nouri-Kamari, Nasim Khonsari
The evaluation of the vulnerability of coupled socio-ecological systems is critical for addressing and preventing the adverse impacts of various environmental hazards and devising strategies for climate change adaptation. The initial step in vulnerability assessment involves exposure assessment, which entails quantifying and mapping the risks posed by multiple environmental hazards, thereby offering valuable insights for the implementation of vulnerability assessment methodologies. Consequently, this study sought to model the exposure of coupled social-ecological systems in mountainous regions to various environmental hazards...
April 27, 2024: Science of the Total Environment
https://read.qxmd.com/read/38684620/recommendations-for-46-xx-congenital-adrenal-hyperplasia-across-two-decades-insights-from-the-north-american-differences-of-sex-development-clinician-survey
#10
JOURNAL ARTICLE
Melissa Gardner, Behzad Sorouri Khorashad, Peter A Lee, Barry A Kogan, David E Sandberg
Several aspects of clinical management of 46,XX congenital adrenal hyperplasia (CAH) remain unsettled and controversial. The North American Disorders/Differences of Sex Development (DSD) Clinician Survey investigated changes, over the last two decades, in clinical recommendations by specialists involved in the management of newborns with DSD. Members of the (Lawson Wilkins) Pediatric Endocrine Society and the Societies for Pediatric Urology participated in a web-based survey at three timepoints: 2003-2004 (T1, n = 432), 2010-2011 (T2, n = 441), and 2020 (T3, n = 272)...
April 29, 2024: Archives of Sexual Behavior
https://read.qxmd.com/read/38684444/an-insight-into-the-last-5-year-patents-on-porphyromonas-gingivalis-and-streptococcus-mutans-the-pivotal-pathogens-in-the-oral-cavity
#11
REVIEW
Bianca Laura Bernardoni, Ilaria D'Agostino, Concettina La Motta, Andrea Angeli
INTRODUCTION: The oral cavity harbors an extensive array of over 700 microorganisms, forming the most complex biome of the entire human body, with bacterial species being the most abundant. Oral diseases, e.g. periodontitis and caries, are strictly associated with bacterial dysbiosis. Porphyromonas gingivalis and Streptococcus mutans stand out among bacteria colonizing the oral cavity. AREAS COVERED: After a brief overview of the bacterial populations in the oral cavity and their roles in regulating (flora) oral cavity or causing diseases like periodontal and cariogenic pathogens, we focused our attention on P...
April 29, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38684327/evaluation-of-the-scat-5-tool-in-the-assessment-of-concussion-in-para-athletes-a-delphi-study
#12
JOURNAL ARTICLE
Bryce Dyer, Osman Hassan Ahmed, Sara Dahlén, Kristin Dalton, Wayne Derman, Amber Donaldson, Kristina Fagher, Jan Lexell, Larissa Pinheiro, Peter Van de Vliet, Richard Weiler, Nick Webborn
OBJECTIVES: To investigate if the sport concussion assessment tool version 5 (SCAT5) could be suitable for application to Para athletes with a visual impairment, a spinal cord injury, or a limb deficiency. METHODS: A 16-member expert panel performed a Delphi technique protocol. The first round encompassed an open-ended questionnaire, with round 2 onwards being composed of a series of closed-ended statements requiring each expert's opinion using a five-point Likert scale...
April 29, 2024: British Journal of Sports Medicine
https://read.qxmd.com/read/38683024/recent-trends-and-challenges-to-overcome-pseudomonas-aeruginosa-infections
#13
REVIEW
Alessandra Ammazzalorso, Arianna Granese, Barbara De Filippis
INTRODUCTION: Pseudomonas aeruginosa (PA) is a Gram-negative bacterium that can cause a wide range of severe infections in immunocompromised patients. The most difficult challenge is due to its ability to rapidly develop multi drug-resistance. New strategies are urgently required to improve the outcome of patients with PA infections. The present patent review highlights the new molecules acting on different targets involved in the antibiotic resistance. AREA COVERED: This review offers an insight into new potential PA treatment disclosed in patent literature...
April 29, 2024: Expert Opinion on Therapeutic Patents
https://read.qxmd.com/read/38682822/aerosol-delivery-in-interstitial-lung-diseases-breakthrough-or-lost-cause
#14
EDITORIAL
Carsten Ehrhardt
No abstract text is available yet for this article.
April 29, 2024: Expert Opinion on Drug Delivery
https://read.qxmd.com/read/38682738/analyses-of-tumor-microenvironment-in-patients-with-advanced-renal-cell-carcinoma-receiving-immunotherapy-meet-uro-18-study
#15
JOURNAL ARTICLE
Fabio Catalano, Matteo Brunelli, Alessio Signori, Pasquale Rescigno, Sebastiano Buti, Luca Galli, Massimiliano Spada, Cristina Masini, Francesca Galuppini, Valerio Gaetano Vellone, Gabriele Gaggero, Marco Maruzzo, Sara Merler, Francesca Vignani, Alessia Cavo, Davide Bimbatti, Michele Milella, Angelo Paolo Dei Tos, Marta Sbaraglia, Veronica Murianni, Alessandra Damassi, Malvina Cremante, Michele Maffezzoli, Miguel Angel Llaja Obispo, Giuseppe Luigi Banna, Giuseppe Fornarini, Sara Elena Rebuzzi
Introduction: The Meet-URO 18 study is a multicentric study of patients with metastatic renal cell carcinoma receiving nivolumab in the second-line and beyond, categorized as responders (progression-free survival ≥ 12 months) and non-responders (progression-free survival < 3 months). Areas covered: The current study includes extensive immunohistochemical analysis of T-lineage markers (CD3, CD4, CD8, CD8/CD4 ratio), macrophages (CD68), ph-mTOR, CD15 and CD56 expression on tumor cells, and PD-L1 expression, on an increased sample size including 161 tumor samples (113 patients) compared with preliminary presented data...
April 29, 2024: Future Oncology
https://read.qxmd.com/read/38682595/current-and-emerging-drugs-for-the-treatment-of-pruritus-an-update-of-the-literature
#16
REVIEW
Rami H Mahmoud, Sarah G Brooks, Gil Yosipovitch
INTRODUCTION: Pruritus, particularly in its chronic form, often imposes significant suffering and reductions in patients' quality of life. The pathophysiology of itch is varied depending on disease context, creating opportunities for unique drug development and multimodal therapy. AREAS COVERED: The purpose of this article is to provide an update of the literature regarding current and emerging therapeutics in itch. We review the multitudes of drug targets available and corresponding drugs that have shown efficacy in clinical trials, with a particular emphasis on phase 2 and 3 trials and beyond...
April 29, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38682580/signal-detection-of-adverse-reactions-for-bendamustine-based-on-fda-adverse-event-reporting-system
#17
JOURNAL ARTICLE
Qing Huang, Yuanbin Wu, Huimin Li
BACKGROUND: This study aimed to analyze the adverse events to bendamustine using data obtained from the Food and Drug Administration open public data project (openFDA) and to provide a reference for its use in clinical practice. RESEARCH DESIGN AND METHODS: Adverse events (AEs) due to bendamustine usage reported from 1 January 2008 to 31 March 2023 were collected from the FDA Adverse Event Reporting System (FAERS). The reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian plausible propagation neural network (BCPNN), and multinomial gamma-Poisson distribution shrinking (MGPS) algorithms were used to identify signs of adverse reactions caused by bendamustine...
April 29, 2024: Expert Opinion on Drug Safety
https://read.qxmd.com/read/38682489/pharmacotherapy-for-gastrointestinal-angiodysplasia-is-it-effective
#18
EDITORIAL
Calvin M Johnson, Nicoletta Nandi, Reena Sidhu
No abstract text is available yet for this article.
April 30, 2024: Expert Opinion on Pharmacotherapy
https://read.qxmd.com/read/38682328/evaluation-of-the-safety-and-efficacy-of-biosimilar-recombinant-growth-hormone-in-children-with-growth-hormone-deficiency-non-inferiority-randomized-parallel-multicentric-and-phase-iii-trial
#19
JOURNAL ARTICLE
Hossein Zaeri, Shahriar Omidvar, Nazli Servatian, Serajaddin Arefnia, Nasrin Khademolreza, Hossein Amini, Behnam Taghavi, Mahin Hashemipour, Peyman Eshraghi, Mahmoud Ghasemi, Robabeh Ghergherehchi, Elham Maleki, Hossein Moravej, Shahab Noorian, Fahimeh Soheilipour, Setila Dalili, Hosseinali Kharazmi, Abdollah Didban, Aliasghar Akhlaghi, Sina Ghaznavi, Majid Shahbazi
OBJECTIVES: This study is designed in order to compare the efficacy and safety of recombinant human growth hormone (rhGH) with the reference brand. METHODS: According to the inclusion criteria, 85 people in 13 Iranian centers were randomly selected to receive biosimilar Somatropin (Somatin®) (44 people) and reference Somatropin (Norditropin®) (41 people) at a dose of 35 µg/kg/d, seven days/week for 12 months. The primary outcomes included height velocity (HV) was measured during 12 months of treatment...
April 29, 2024: Expert Opinion on Drug Safety
https://read.qxmd.com/read/38682280/novel-investigational-drugs-for-alopecia-areata-and-future-perspectives
#20
REVIEW
Ivana Chim, Ragini Ghiya, Rodney D Sinclair, Samantha Eisman
INTRODUCTION: Alopecia areata (AA) is an immune-mediated disease that causes non-scarring hair loss. While acute, solitary patches often spontaneously remit, developing secondary patches or failure of the disease to resolve within 6-12 months predicts a poor prognosis, with an increased risk of alopecia totalis or universalis. Chronic AA increases the risk of depression and suicidality and reduces quality of life. Treatment options for chronic or acute diffuse AA were previously limited to corticosteroids and traditional immunomodulators...
April 29, 2024: Expert Opinion on Investigational Drugs
keyword
keyword
67818
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.